Amino acids are essential to support protein synthesis, which is required for cell growth and proliferation. Amino acid uptake into the cell is mediated by amino acid transporters located on the plasma membrane.
The system L amino acid transporters are an amino acid transport system that transports neutral amino acids, including several essential amino acids, in a Na ϩ -independent manner. 1, 3) It is a major route for providing living cells, including cancer cells, with amino acids. 1, 3) We isolated LAT1 (L-type amino acid transporter 1), the first isoform of a system L amino acid transporter, from C6 rat glioma cells. 4) Subsequently, we and other researchers cloned LAT2 (L-type amino acid transporter 2), the second isoform of a system L amino acid transporter. [5] [6] [7] The structure and function of LAT1 are very similar to those of LAT2. Both isoforms are predicted to be 12-membrane-spanning proteins. [4] [5] [6] [7] They require an additional single-membranespanning protein, the heavy chain of 4F2 antigen (4F2hc), for their functional expression in the plasma membrane. [4] [5] [6] [7] [8] [9] [10] [11] [12] Both LAT1 and LAT2 form a heterodimeric complex via a disulfide bond with 4F2hc. [4] [5] [6] [7] [8] [9] [10] [11] [12] However, LAT2 is more ubiquitously expressed than LAT1, and it transports not only large neutral amino acids, but also small neutral amino acids in a fashion that appears to have broader substrate selectivity than LAT1. [4] [5] [6] [7] [9] [10] [11] [12] [13] [14] In addition, LAT1 is highly expressed in malignant tumors, presumably to support their continuous growth and proliferation. 4, 8, 15, 16) 2-Aminobicyclo-(2,2,1)-heptane-2-carboxylic acid (BCH) is a model compound for the study of amino acid transporters, as it is a system L selective inhibitor. 1, 17) Because system L amino acid transporters transport neutral amino acids, including several essential amino acids, if they are blocked in living cells by a specific inhibitor such as BCH, the cells would be damaged; damage would be caused specifically by the deprivation of amino acids necessary for protein synthesis, cell growth and proliferation. In addition, several reports have demonstrated that amino acid uptake increased during the proliferation process of cancer cells to support DNA and protein biosynthesis. [18] [19] [20] It is proposed that the manipulation of system L activity, particularly that of LAT1, would have therapeutic implications. The inhibition of LAT1 activity in cancer cells could be effective in the suppression of cancer cell growth by depriving cancer cells of essential amino acids. 17, 21) However, the mechanism by which inhibition of LAT1 can cause cancer cell growth suppression or cytotoxicity of cancer cells is not entirely clear.
In this study, we examined the effect of BCH on cell growth and its mechanism of cell growth suppression in cancer cells. We used cells that highly expressed only LAT1 among all the system L transporters. [22] [23] [24] Our results show that the system L selective inhibitor BCH, at suitable concentrations, can induce the suppression of cell growth and cancer cell apoptosis. Cell Cultures The KB cells were grown in MEM containing NEAA (non-essential amino acids) at a ratio of 100 : 1, and the media was supplemented with 5% FBS. The Saos2 cells and C6 cells were grown in the DMEM supplemented with 10% FBS. All cells were maintained as monolayers in plastic culture plates at 37°C in a humidified atmosphere containing 5% CO 2 .
MATERIALS AND METHODS

Materials
Transport Measurements in Cells To examine the inhibition of amino acid transport by BCH in cells, uptake experiments were performed using [
14 C]L-leucine, one of the substrates of system L amino acid transporters, as described previously. 17, 22) Because the uptake of amino acids induced by system L amino acid transporters is not dependent on Na ϩ , 4, 7, 8, 13) the uptake experiments were performed in Na 17, 22) the uptake measurements were performed for 1 min. Uptake was terminated by removing the uptake solution followed by washing three times with ice-cold uptake solution. Then, cells were solubilized with 0.1 N NaOH, and radioactivity was counted by liquid scintillation spectrometry. The values are expressed as percentage of activity. For the measurement of the uptake of [
14 C]L-leucine, four to six wells of cells were used for each data point. To confirm the reproducibility of the results, three separate experiments were performed for each measurement. Results from the representative experiments are shown. To determine the IC 50 value for BCH, the uptake of 1 mM [ 14 C]L-leucine was measured in the presence of BCH 0, 1, 3, 10, 30, 100, 300, 1000 and 3000 mM.
Inhibition of Cell Growth by BCH (MTT Assay)
The cell viability test was performed according to the previouslydescribed method, 25, 26) with minor modifications. The cells were seeded at a concentration of 5ϫ10 3 cells/well in 24-well plates. After 24 h growth, the cells were treated with BCH at various concentrations and incubation times. The cell viability was assessed using MTT assay. Three separate experiments were performed for each concentration/exposure time combination.
DNA Fragmentation Analysis Following treatment with 20 mM BCH for various incubation times, approximately 5ϫ10 6 cells were collected and transferred to lysis buffer containing 100 mM NaCl, 10 mM EDTA, 300 mM TrisHCl, pH 7.5, 200 mM sucrose, 0.5% SDS and 0.5 mg/ml proteinase K and incubated at 65°C. DNA was extracted with an equal volume of phenol/chloroform/isoamylalcohol (25 : 24 : 1, v/v) and precipitated with ethanol. The DNA was resuspended in Tris-EDTA buffer, pH 8.0 containing 5 mg/ml DNase-free RNase and incubated at 37°C for 1 h. The DNA was visualized on 1.5% agarose gel in the presence of 0.5 mg/ml ethidium bromide.
TUNEL Assay To examine cellular apoptosis induced by BCH treatment, the TUNEL assay was performed. The cells were seeded at a concentration of 5ϫ10 3 cells/well in 24-well plates. After 24 h growth, the cells were treated with 20 mM BCH at various incubation times. The TUNEL assay was performed using a DeadEnd TM Colorimetric TUNEL System kit (Promega Co., Madison, WI, U.S.A.) in accordance with the manufacturer's instructions.
Immunoblotting The cells were treated with 20 mM BCH at various incubation times. Immunoblotting was performed according to the previously-described method, 27, 28) with minor modifications. The anti-caspase-3 or anti-caspase-7 antibody (1 : 1000 dilution, Cell Signaling Technology, Inc., Danvers, MA, U.S.A.) was used as the primary antibody.
Determination of Caspase Activation The activity of caspase-3/7 was determined using the cell-permeable fluorogenic substrate PhiPhiLux-G 1 D 2 (OncoImmunin, Inc., Gaithersburg, MD, U.S.A.), which was used according to the manufacturer's instructions, and visualized by fluorescence microscopy.
Data Analysis All experiments were performed in triplicate. Results are presented as meanϮS.E.M. Statistical significance was analyzed by using Student's t-test for two groups and one way analysis of variance for multi-group comparisons. pϽ0.05 is considered statistically significant. 
RESULTS
Inhibition of [
Cancer Cell Growth Inhibition by BCH
To analyze the effect of BCH on the viability of cancer cells, the cells were treated with BCH at various concentrations and incubation times, and then the MTT assay was performed. From 0.3 to 50 mM treatment of BCH, the inhibition of cancer cell growth depended on the BCH treatment time (Fig. 2) . When the cells were treated with BCH at 0.3, 1, 3, 10, 20 and 50 mM, BCH inhibited the proliferation of cancer cells in a dose-dependent manner (Fig. 2) . The IC 50 value for each time point of BCH treatment is shown in Table 1 . BCH had similar cytotoxicities and IC 50 values in all three cancer cell types (Table 1) .
DNA Fragmentation and TUNEL Assays Increased cellular apoptosis is only one among several possible mechanisms involved in reduced cell proliferation. To determine if apoptosis is indeed the underlying mechanism for the reduced cell proliferation we had observed, the cancer cells treated with BCH were subjected to DNA fragmentation and TUNEL assays. As shown in Fig. 3A , the formation of a DNA ladder in the KB, Saos2 and C6 cells treated with 20 mM BCH was observed in a time-dependent manner. As expected, the proportion of TUNEL-positive KB, Saos2 and C6 cells was significantly increased with 20 mM BCH treatment compared with untreated control (Fig. 3B) .
Activation of Caspases by BCH in Cancer Cells
The levels of procaspase-3 and procaspase-7 were examined by Western blot analysis and detected by fluorescence microscopy using a selective fluorogenic substrate since caspase-3 and caspase-7 are effector caspases of apoptotic cell death. Treatment with 20 mM BCH significantly promoted proteolytic cleavage of procaspase-7 in the KB, Saos2 and C6 cells, with a decrease in the amount of procaspase-7 (Fig.  4) . In addition, BCH enhanced proteolytic cleavage of procaspase-3 in the KB and C6 cells, with a decrease in the amount of procaspase-3; however, this change was not observed in the Saos2 cells (Fig. 4) . Furthermore, activation of caspase-3/7 in BCH-treated cells (KB, Saos2 and C6) was confirmed by fluorescence microscopy using fluorogenic sub- Cells were incubated with or without BCH for 0, 1, 2 and 3 d.
strate. As shown in Fig. 5 , BCH treatment led to activate the caspase-3/7 in the KB, Saos2 and C6 cells.
DISCUSSION
In this study, we investigated the effects of BCH on cell growth and its mechanism of growth suppression in cancer cells. In our previous studies, [22] [23] [24] we examined the expression of the system L amino acid transporters in several cancer cell types. The KB human oral epidermoid carcinoma cells and C6 rat glioma cells expressed only LAT1 with 4F2hc but not LAT2 in the plasma membrane, and the Saos2 human osteogenic sarcoma cells mainly expressed LAT1 with 4F2hc, with weak expression of LAT2. We used the KB, Saos2 and C6 cells for this study.
BCH is an amino acid-related compound that has been used as a selective inhibitor of the system L amino acid transporters, including LAT1 and LAT2. 1, 17) In this study, BCH completely inhibited L-leucine uptake, as a model neutral amino acid, in a concentration-dependent manner with similar IC 50 values in the KB, Saos2 and C6 cells (Fig. 1) . This result suggests that LAT1 plays an important role in neutral amino acid transport, including L-leucine transport, in cells that highly express LAT1 only.
In the MTT assay, BCH inhibited cell growth in a time-dependent manner in the KB, Saos2 and C6 cell types (Fig. 2) . This corresponded with the results of several compounds (paradol, norcantharidin, baccatin, etc.) 25, 29, 30) that have anticancer effects via the suppression of cancer cell growth in a time-dependent manner. LAT1 is upregulated in cancer cells to support their continuous growth and proliferation. 4, 8, 15, 16) LAT1 was also highly expressed in these cells, and neutral amino acids were transported for cell growth and proliferation. If the activity of LAT1 was inhibited by BCH, the intracellular depletion of neutral amino acids, including essential amino acids necessary for cell growth, may be induced. The results suggest that cancer cell growth was inhibited. As shown in Fig. 1 , although 3 mM BCH completely inhibited leusine uptake, it was not enough to suppress the cell growth and apoptosis. We speculated that uptake experiment is short term view but apoptosis induction is long term view because BCH compete with extracellular amino acid and slowly induced apoptosis via caspase activation. In order to detect apoptosis, high concentration of BCH was needed for inhibition of highly proliferous cancer cells.
In this study, treatment with BCH induced internucleosomal DNA fragmentation and the increase of TUNEL-positive cells in KB, Saos2 and C6 cells, suggesting apoptotic cell death (Fig. 3) . These results indicate that BCH inhibited the growth of these cells by activating cell apoptosis.
The activation of a family of intracellular cysteine proteases, called caspases, is known to play an important role in the initiation and execution of apoptosis induced by various stimuli. 31, 32) Among the caspases identified in mammalian cells, caspase-3 and caspase-7 may serve as effector caspases of apoptotic cell death. [31] [32] [33] Caspase-3 and caspase-7 are synthesized as inactive proenzymes (of sizes 32 kDa and 35 kDa, respectively), which require proteolytic activation. [31] [32] [33] Our results show that high levels of procapase-7 were present in BCH-untreated cancer cells, and the amount of procaspase-7 was decreased after BCH treatment in the KB, Saos2 and C6 cells (Fig. 4) . Our results also showed that BCH treatment promoted proteolytic cleavage of procaspase-3 in the KB and C6 cells, with a decrease in the amount of procaspase-3, but this was not seen in the Saos2 cells (Fig.  4) . These results suggest that BCH induces apoptotic cell death through caspase-3-and caspase-7-dependent processing in KB and C6 cells, while on the other hand, BCH induces apoptotic cell death only through caspase-7-dependent processing in Saos2 cells (Fig. 5) . The mechanisms of apoptosis induced by BCH are not yet completely understood. Further studies will reveal the precise cellular and molecular mechanisms of apoptosis induced by BCH.
In conclusion, we found that inhibition of the amino acid transporter LAT1 by BCH led to apoptotic cell death in cancer cells by inducing intracellular depletion of essential neutral amino acids such as L-leucine. Moreover, LAT1 could be a new target for suppression of the growth of cancer cells.
